TABLE 2.

Summary of PSQ results from clinical isolates and clinical specimens

PSQ result (no.)	Phenotypic DST result (no. of samples)b						Accuracy analysis resultsa (%)
	Clinical isolates		Clinical specimens		Combined		Correlation	Sensitivity	Specificity
	R	S	R	S	R	S
INH (245)
Mutations detected	78	0	21	0	99	0	94.3	87.6	100
No mutations	10	42	4	90	14	132
RIF (237)
Mutations detected	67	3	12	3	79	6c	98.7c	96.3	100c
No mutations	1	55	2	94	3	149
fQs (125)d
Mutations detected	17	0	3	0	20	0	97.6	87.0	100
No mutations	2	79	1	23	3	102
AMK (120)
Mutations detected	14	1	1	0	15	1	99.2	100	99.0
No mutations	0	79	0	25	0	104
CAP (119)
Mutations detected	14	1	1	0	15	1	99.2	100	99.0
No mutations	0	79	0	24	0	103
KAN (55)
Mutations detected	11	0	1	0	12	0	96.4	85.7	100
No mutations	2	28	0	13	2	41

^aThe accuracy analysis was performed with combined data from clinical isolates and clinical specimens. The accuracy analysis for the clinical isolates only is presented in Table S4 in the supplemental material and that for the clinical specimens in Table S5 in the supplemental material.

^bR, resistant; S, susceptible.

^cThe analysis for RIF was based on known associations of specific rpoB mutations with RIF resistance or susceptibility. The mutations not conferring resistance were CAC526AAC (n = 2) and TTC514TTT (n = 4). The analysis excluded samples with rpoB mutations with unknown or inconsistent associations with RIF resistance, i.e., CTG511CCG, GAC516TTC, CAC526TGC, CAC526AGC, CAC526TCC, and CTG533CCG. For an analysis based on the general assumption that any rpoB mutation is a predictor of RIF resistance, the correlation and specificity would be 96.2% and 96.1%, respectively.

^dAn isolate was classified as fQ resistant when it tested resistant to one of the fQs at its test concentration, i.e., 2 μg/ml for ofloxacin, 1.5 μg/ml for levofloxacin, and 0.25 μg/ml for moxifloxacin.